Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study.
Morland D, Kanagaratnam L, Hubelé F, Toussaint E, Choquet S, Kas A, Caquot PA, Haioun C, Itti E, Leprêtre S, Decazes P, Bijou F, Schwartz P, Jacquet C, Chauchet A, Matuszak J, Kamar N, Payoux P; K-VIROGREF Study Group; Durot E. Morland D, et al. Among authors: durot e. EJNMMI Res. 2024 May 27;14(1):49. doi: 10.1186/s13550-024-01111-8. EJNMMI Res. 2024. PMID: 38801646 Free PMC article.
Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.
Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Zanwar S, et al. Among authors: durot e. J Clin Oncol. 2024 May 24:JCO2302066. doi: 10.1200/JCO.23.02066. Online ahead of print. J Clin Oncol. 2024. PMID: 38788183
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, Hänel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M. Fischer L, et al. Among authors: durot e. Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254-2. Online ahead of print. Leukemia. 2024. PMID: 38678093
High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia.
Durot E, Roosweil D, Chauchet A, Decroocq J, Di Blasi R, Gastinne T, Bensaber H, Cheminant M, Jacquet C, Guidez S, Gros FX, Bachy E, Coste A, Cony-Makhoul P, Treon SP, Delmer AJ, Reshef R, Le Gouill S, Castillo JJ, Houot R. Durot E, et al. Blood. 2024 Apr 26:blood.2024024452. doi: 10.1182/blood.2024024452. Online ahead of print. Blood. 2024. PMID: 38669635
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
Wilson MR, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri AJM, El-Galaly T, Cwynarski K, McKay P, Eyre TA. Wilson MR, et al. Among authors: durot e. Am J Hematol. 2024 Feb;99(2):E46-E50. doi: 10.1002/ajh.27167. Epub 2023 Nov 30. Am J Hematol. 2024. PMID: 38037530 No abstract available.
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.
Camus V, Viailly PJ, Drieux F, Veresezan EL, Sesques P, Haioun C, Durot E, Patey M, Rossi C, Martin L, Rainville V, Bohers E, Ruminy P, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Willaume A, Antier C, Lazarovici J, Lévêque E, Decazes P, Becker S, Tonnelet D, Berriolo-Riedinger A, Gaulard P, Tilly H, Molina TJ, Traverse-Glehen A, Jardin F. Camus V, et al. Among authors: durot e. Blood Adv. 2023 Dec 12;7(23):7331-7345. doi: 10.1182/bloodadvances.2023011169. Blood Adv. 2023. PMID: 37862676 Free PMC article.
Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.
Rodier C, Kanagaratnam L, Morland D, Herbin A, Durand A, Chauchet A, Choquet S, Colin P, Casasnovas RO, Deconinck E, Godard F, Delmer A, Rossi C, Durot E. Rodier C, et al. Among authors: durot e. Hemasphere. 2023 Apr 26;7(5):e861. doi: 10.1097/HS9.0000000000000861. eCollection 2023 May. Hemasphere. 2023. PMID: 37125257 Free PMC article.
44 results